The Virus Biology Scientific Research Support Component will provide molecular approaches, reagents and service to CHAVI-ID investigators geared toward determining whether T/F viruses have unique biological properties that can be exploited as targets for rational immunogen design. The overall goal is to understand the protective humoral, cellular and innate responses to HIV-1 infection, and to study the structural biology and virology of the T/F virus as a pathogen and immunogen. The Virus Biology Support Component will also explore the impact of Env quasispecies evolution on the development of broadly neutralizing antibodies and characterize human and primate vaccine breakthrough infections to determine whether certain vaccine modalities influence the number, composition, and phenotype of transmitted viruses.
Specific Aims Aim 1: Determine whether T/F viruses have common biological properties that comprise favorable targets for vaccine intervention Aim 2: Examine how the evolution of the Env quasispecies contributes to the development of broad neutralizing antibodies Aim 3: Genetically characterize SIV/SHIV challenge stocks and perform sieve analyses of breakthrough infections in actively or passively immunized primates Aim 4: Perform sieve analyses of breakthrough infections in vaccinated humans. These studies will support the B Cell Research Focus as well as Computational, Antibody Sequencing, Structural Biology, Neutralizing Antibodies and NHP SCRCs and will help to find new targets in the HIV-1 transmission pathway that will sharpen the focus of vaccine development efforts.
The Virus Biology Support Component has developed a novel set of virological approaches that are geared toward identifying vulnerabilities of HI V-1 T/F viruses and their progeny that can be exploited for immunogen design. Using these novel approaches, the SRSC will provide expertise and generate a comprehensive set of well-characterized reagents that will contribute vitally to the objectives of the overall CHAVI-ID consortium.
|Pollara, Justin; Easterhoff, David; Fouda, Genevieve G (2017) Lessons learned from human HIV vaccine trials. Curr Opin HIV AIDS 12:216-221|
|Arakelyan, Anush; Fitzgerald, Wendy; King, Deborah F et al. (2017) Flow virometry analysis of envelope glycoprotein conformations on individual HIV virions. Sci Rep 7:948|
|Go, Eden P; Ding, Haitao; Zhang, Shijian et al. (2017) Glycosylation Benchmark Profile for HIV-1 Envelope Glycoprotein Production Based on Eleven Env Trimers. J Virol 91:|
|Verkoczy, Laurent; Alt, Frederick W; Tian, Ming (2017) Human Ig knockin mice to study the development and regulation of HIV-1 broadly neutralizing antibodies. Immunol Rev 275:89-107|
|Haynes, Barton F; Mascola, John R (2017) The quest for an antibody-based HIV vaccine. Immunol Rev 275:5-10|
|Bonsignori, Mattia; Liao, Hua-Xin; Gao, Feng et al. (2017) Antibody-virus co-evolution in HIV infection: paths for HIV vaccine development. Immunol Rev 275:145-160|
|Kelsoe, Garnett; Haynes, Barton F (2017) What Are the Primary Limitations in B-Cell Affinity Maturation, and How Much Affinity Maturation Can We Drive with Vaccination? Breaking through Immunity's Glass Ceiling. Cold Spring Harb Perspect Biol :|
|Herschhorn, Alon; Sodroski, Joseph (2017) An entry-competent intermediate state of the HIV-1 envelope glycoproteins. Receptors Clin Investig 4:|
|Ding, Shilei; Verly, Myriam M; Princiotto, Amy et al. (2017) Short Communication: Small-Molecule CD4 Mimetics Sensitize HIV-1-Infected Cells to Antibody-Dependent Cellular Cytotoxicity by Antibodies Elicited by Multiple Envelope Glycoprotein Immunogens in Nonhuman Primates. AIDS Res Hum Retroviruses 33:428-431|
|Espy, Nicole; Pacheco, Beatriz; Sodroski, Joseph (2017) Adaptation of HIV-1 to cells with low expression of the CCR5 coreceptor. Virology 508:90-107|
Showing the most recent 10 out of 220 publications